FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasiiiigton,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours ner resnonse.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* FRATES JAMES M (Last) (First) (Middle)						2. Issuer Name and Ticker or Trading Symbol Amylyx Pharmaceuticals, Inc. [AMLX] 3. Date of Earliest Transaction (Month/Day/Year) 03/16/2023								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Financial Officer					
C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	A	02141		_									X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)		_ R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								I to					
		Tab	le I - I	Non-Deri	ivativ	e Sec	curities	s Ac	quire	d, D	isposed o	f, or Be	eneficial	ly Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y						Execution Date,		·			Acquired (A) or f (D) (Instr. 3, 4 and 5)		Secu Bene Own	5. Amount of Securities Beneficially Owned Following Reported		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Tran	saction(s) : 3 and 4)			(111341. 4)	
Common Stock 03/16/202						23			S ⁽¹⁾		30,796	D	\$31.8593	(2)	3,213	,213			
Common Stock 03/16/202					2023	23			S ⁽¹⁾		1,704	D	\$32.4649)(3)	1,509		D		
Common Stock 03/16/202				2023	23		Α		21,667(4)	A	\$0.00		23,176		D				
		-	Table								posed of,			Owned	I				
1. Title of Derivative Security (Instr. 3)	of ive Conversion or Exercise of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year) 8. A. Deemed Execution Date, if any (Month/Day/Year) 8. A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date Expiration Date Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		8. Price Derivativ Security (Instr. 5)	erivative derivative ecurity Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
Stock Option (right to buy)	\$32.08	03/16/2023			A		97,500	(5)	(S		03/16/2033	Common Stock	97,500	\$0.00	97,50	0	D		

Explanation of Responses:

- 1. These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$31.33 to \$32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$32.33 to \$32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 4. The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
- 5. 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.

Remarks:

/s/ Joshua B. Cohen, as Attorney in Fact

03/20/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.